JP2016521553A - インフルエンザウイルス再集合 - Google Patents

インフルエンザウイルス再集合 Download PDF

Info

Publication number
JP2016521553A
JP2016521553A JP2016517733A JP2016517733A JP2016521553A JP 2016521553 A JP2016521553 A JP 2016521553A JP 2016517733 A JP2016517733 A JP 2016517733A JP 2016517733 A JP2016517733 A JP 2016517733A JP 2016521553 A JP2016521553 A JP 2016521553A
Authority
JP
Japan
Prior art keywords
seq
influenza
segment
strain
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016517733A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521553A5 (https=
Inventor
ピーター メイソン，
ピーター メイソン，
ピラダ スッパピパット，
ピラダ スッパピパット，
ラウル ゴミラ，
ラウル ゴミラ，
フィリップ ドルミッチャー，
フィリップ ドルミッチャー，
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド
シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー, シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド, シンセティック ジェノミクス ヴァクシンズ， インコーポレーテッド filed Critical ノバルティス アーゲー
Publication of JP2016521553A publication Critical patent/JP2016521553A/ja
Publication of JP2016521553A5 publication Critical patent/JP2016521553A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16161—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2016517733A 2013-06-06 2014-06-06 インフルエンザウイルス再集合 Ceased JP2016521553A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361832091P 2013-06-06 2013-06-06
US61/832,091 2013-06-06
EP13179013 2013-08-01
EP13179013.1 2013-09-26
PCT/IB2014/062030 WO2014195920A2 (en) 2013-06-06 2014-06-06 Influenza virus reassortment

Publications (2)

Publication Number Publication Date
JP2016521553A true JP2016521553A (ja) 2016-07-25
JP2016521553A5 JP2016521553A5 (https=) 2017-07-20

Family

ID=48900885

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016517733A Ceased JP2016521553A (ja) 2013-06-06 2014-06-06 インフルエンザウイルス再集合

Country Status (12)

Country Link
US (1) US10329537B2 (https=)
EP (1) EP3004332A2 (https=)
JP (1) JP2016521553A (https=)
KR (1) KR20160014657A (https=)
CN (1) CN105722976A (https=)
AU (1) AU2014276418A1 (https=)
BR (1) BR112015030582A2 (https=)
CA (1) CA2914604A1 (https=)
HK (1) HK1222882A1 (https=)
MX (1) MX2015016755A (https=)
SG (1) SG11201509985XA (https=)
WO (1) WO2014195920A2 (https=)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020010711A (ja) * 2013-07-15 2020-01-23 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US11046934B2 (en) 2014-06-20 2021-06-29 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
JP2021518150A (ja) * 2018-03-21 2021-08-02 ネイチャー テクノロジー コーポレーション 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US12076387B2 (en) 2010-03-23 2024-09-03 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US12144857B2 (en) 2018-08-20 2024-11-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US12251436B2 (en) 2017-10-25 2025-03-18 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US12365880B2 (en) 2020-01-24 2025-07-22 The University Of Tokyo Recombinant influenza viruses with stabilized NA
US12364748B2 (en) 2016-02-19 2025-07-22 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
US12410409B2 (en) 2011-08-26 2025-09-09 Wisconsin Alumni Research Foundation (Warf) Influenza viruses with mutant PB2 gene segment as live attenuated vaccines

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2493912B1 (en) 2009-10-26 2020-07-29 Wisconsin Alumni Research Foundation High titer recombinant influenza viruses with enhanced replication in vero cells
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
US11013795B2 (en) 2015-06-26 2021-05-25 Seqirus UK Limited Antigenically matched influenza vaccines
US9890363B2 (en) 2015-07-06 2018-02-13 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
CN109312310B (zh) * 2016-07-15 2022-08-02 一般财团法人阪大微生物病研究会 重配流感病毒的制备方法
ES2991988T3 (es) 2017-10-30 2024-12-05 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivación de virus con envoltura lipídica
CN108048476B (zh) * 2017-11-21 2020-09-08 浙江迪福润丝生物科技有限公司 一种制备区分免疫和感染动物h9亚型禽流感疫苗株的方法及应用
CN108018300B (zh) * 2017-11-21 2020-08-28 浙江迪福润丝生物科技有限公司 区分免疫和感染动物h7亚型禽流感疫苗株及其制备方法和应用
EP3914295A2 (en) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutations that confer genetic stability to additional genes in influenza viruses
CN113527443B (zh) * 2020-04-16 2023-03-07 中国科学院微生物研究所 甲型流感病毒pb1蛋白t细胞表位多肽片段及其应用
KR20230171446A (ko) * 2021-04-15 2023-12-20 주식회사 바이오오케스트라 단백질 발현을 증진시킬 수 있는 폴리뉴클레오티드 및 이의 용도
CN114058742B (zh) * 2022-01-18 2022-04-22 广州科方生物技术股份有限公司 一种引物探针组合物、包含其的试剂盒及其检测方法
CN119452088A (zh) * 2022-05-31 2025-02-14 Vlp治疗日本公司 修饰疫苗设计开发
CN116144612B (zh) * 2022-12-08 2023-11-10 广州医科大学附属第一医院（广州呼吸中心） 重组乙型流感病毒及其制备方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530499A (ja) * 2009-06-24 2012-12-06 メディカゴ インコーポレイテッド ヘマグルチニンを含むキメラインフルエンザウイルス様粒子

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DE19612966B4 (de) 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
DE19612967A1 (de) 1996-04-01 1997-10-02 Behringwerke Ag Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren
TW570803B (en) 1997-04-09 2004-01-11 Duphar Int Res Influenza vaccine
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
PL355287A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Intranasal influenza virus vaccine
KR100797547B1 (ko) 2000-03-03 2008-01-24 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 무혈청 배양 및 부유 배양에서 사용할 수 있는 세포 및상기 세포를 사용하여 백신용 바이러스를 제조하는 방법
GB0024089D0 (en) 2000-10-02 2000-11-15 Smithkline Beecham Biolog Novel compounds
EP2281573A3 (en) 2001-02-23 2011-12-07 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
CA2438960A1 (en) 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
MY134424A (en) 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
US7566458B2 (en) * 2003-06-16 2009-07-28 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
KR20110132416A (ko) 2004-04-05 2011-12-07 화이자 프로덕츠 인코포레이티드 미세유체화된 수중유 유화액 및 백신 조성물
WO2005113756A1 (en) 2004-05-14 2005-12-01 Glaxosmithkline Biologicals S.A. Method
JP2007537760A (ja) 2004-05-20 2007-12-27 アイディー バイオメディカル コーポレイション インフルエンザワクチンを製造するためのプロセス
DK2368975T3 (en) 2004-12-23 2015-01-05 Medimmune Llc Non-tumorigenic MDCK cell line for the propagation of viruses
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
EP1917352A4 (en) 2005-06-21 2009-03-25 Medimmune Vaccines Inc METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
ES2525518T3 (es) 2005-11-01 2014-12-26 Novartis Vaccines And Diagnostics Gmbh Vacunas virales derivadas de células con niveles reducidos de ADN celular residual
JP2009514844A (ja) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル スプリットインフルエンザワクチン用のアジュバントとしての遊離水相界面活性剤を含むエマルション
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
DK2016194T3 (en) 2006-04-19 2015-06-15 Medimmune Llc METHODS AND COMPOSITIONS FOR EXPRESSION OF VIRAL NEGATIVE SENSE RNA IN DOG CELLS
EA015817B1 (ru) 2006-10-12 2011-12-30 Глаксосмитклайн Байолоджикалс С.А. Иммуногенная композиция, содержащая адъювант в виде эмульсии "масло в воде"
PT2121011E (pt) 2006-12-06 2014-07-31 Novartis Ag Vacinas compreendendo um antigénio a partir de quatro estirpes do vírus da gripe
EP2045323A1 (en) 2007-10-05 2009-04-08 Avir Green Hills Biotechnology Research Development Trade Ag Linear expression constructs for production of influenza virus particles
EA021009B1 (ru) 2009-05-21 2015-03-31 Новартис Аг ОБРАТНАЯ ГЕНЕТИКА С ИСПОЛЬЗОВАНИЕМ НЕЭНДОГЕННЫХ ПРОМОТОРОВ pol I
CN104862335A (zh) 2009-07-31 2015-08-26 诺华股份有限公司 反向遗传系统
CA2778332A1 (en) 2009-10-20 2011-04-28 Novartis Ag Improved reverse genetics methods for virus rescue
CN103608453B (zh) * 2012-03-02 2018-07-24 思齐乐 流感病毒重配
US9982240B2 (en) * 2012-08-03 2018-05-29 Sanofi Pasteur Production of infectious influenza viruses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530499A (ja) * 2009-06-24 2012-12-06 メディカゴ インコーポレイテッド ヘマグルチニンを含むキメラインフルエンザウイルス様粒子

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A reassortment-incompetent live attenuated influenza virus vaccine for protection against pandemic v", JOURNAL OF VIROLOGY, vol. 85, JPN6018017350, 2011, pages 6832 - 43, ISSN: 0003948015 *
JOURNAL OF VIROLOGY, JPN6018017352, 2003, pages 77, ISSN: 0004079885 *
MICROBES AND INFECTION, vol. 6, JPN6018017351, 2004, pages 579 - 583, ISSN: 0004079884 *

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12076387B2 (en) 2010-03-23 2024-09-03 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
US12410409B2 (en) 2011-08-26 2025-09-09 Wisconsin Alumni Research Foundation (Warf) Influenza viruses with mutant PB2 gene segment as live attenuated vaccines
JP2020010711A (ja) * 2013-07-15 2020-01-23 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
US11046934B2 (en) 2014-06-20 2021-06-29 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US11802273B2 (en) 2014-06-20 2023-10-31 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
US12364748B2 (en) 2016-02-19 2025-07-22 Wisconsin Alumni Research Foundation (Warf) Influenza B virus replication for vaccine development
US12251436B2 (en) 2017-10-25 2025-03-18 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
JP2024138410A (ja) * 2018-03-21 2024-10-08 アルデブロン，エル．エル．シー． 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
JP7520719B2 (ja) 2018-03-21 2024-07-23 アルデブロン，エル．エル．シー． 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
US12600984B2 (en) 2018-03-21 2026-04-14 Aldevron, L.L.C. Viral and non-viral nanoplasmid vectors with improved production
JP2021518150A (ja) * 2018-03-21 2021-08-02 ネイチャー テクノロジー コーポレーション 生成が改良されたウイルス及び非ウイルスのナノプラスミドベクター
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US12144857B2 (en) 2018-08-20 2024-11-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
US11851648B2 (en) 2019-02-08 2023-12-26 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US12258557B2 (en) 2019-02-08 2025-03-25 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
US12122807B2 (en) 2019-05-01 2024-10-22 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11390649B2 (en) 2019-05-01 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication for vaccine development
US11807872B2 (en) 2019-08-27 2023-11-07 Wisconsin Alumni Research Foundation (Warf) Recombinant influenza viruses with stabilized HA for replication in eggs
US12365880B2 (en) 2020-01-24 2025-07-22 The University Of Tokyo Recombinant influenza viruses with stabilized NA
US12290562B2 (en) 2020-03-25 2025-05-06 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses

Also Published As

Publication number Publication date
HK1222882A1 (zh) 2017-07-14
MX2015016755A (es) 2016-04-13
SG11201509985XA (en) 2016-01-28
BR112015030582A2 (pt) 2017-08-29
AU2014276418A1 (en) 2016-01-21
CN105722976A (zh) 2016-06-29
CA2914604A1 (en) 2014-12-11
US20160122726A1 (en) 2016-05-05
EP3004332A2 (en) 2016-04-13
KR20160014657A (ko) 2016-02-11
US10329537B2 (en) 2019-06-25
WO2014195920A3 (en) 2015-05-28
WO2014195920A2 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
JP6279503B2 (ja) インフルエンザウイルスの再集合
US10329537B2 (en) Influenza virus reassortment
JP6082483B2 (ja) インフルエンザウイルス再集合方法
JP6525469B2 (ja) インフルエンザｂ型ウイルス再集合
JP6421128B2 (ja) リアソータントインフルエンザａウイルス
JP5836266B2 (ja) 非内因性ｐｏｌＩプロモーターを使用した逆遺伝学
JP2016104004A (ja) ウイルスレスキューのための改善された逆遺伝学
JP2016521282A (ja) インフルエンザワクチンにおけるナルコレプシーのリスクの回避
JP2016506724A (ja) インフルエンザウイルスの再集合
AU2014203051C1 (en) Influenza Virus Reassortment

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170605

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180420

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180515

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180815

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190327

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190722

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20191121